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Fluorescence correlation spectroscopy and the newly synthesized Alexa532-ET1 were used to study the dynamics of the endothelin
ETA receptor-ligand complex alone and under the inﬂuence of a semisynthetic selective antagonist and a fungal extract on living
A10 cells. Dose-dependent increase of inositol phosphate production was seen for Alexa532-ET1, and its binding was reduced to
8% by the selective endothelin ETA antagonist BQ-123, conﬁrming the speciﬁc binding of Alexa532-ET1 to the endothelin ETA
receptor. Two diﬀerent lateral mobilities of the receptor-ligand complexes within the cell membrane were found allowing the dis-
crimination of diﬀerent states for this complex. BQ-123 showed a strong binding aﬃnity to the “inactive” receptor state charac-
terized by the slow diﬀusion time constant. A similar eﬀect was observed for the fungal extract, which completely displaced
Alexa532-ET1 from its binding to the “inactive” receptor state. These ﬁndings suggest that both BQ-123 and the fungal extract act
as inverse agonists.
1.Introduction
Theecologicalandpharmacologicalimpactofmarineorgan-
isms is a hot topic in drug discovery programs around the
globe. The sustainable use of natural products in investiga-
tions aiming at ﬁnding new active metabolites with new
pharmaceutical and biotechnological applications remains a
major focal point of research [1]. Microorganisms, for in-
stance,aretargetedasasuitablerenewablesourceofbioactive
substances, and the exploration of those microbes coming
from unusual habitats like the ocean increases the chances
of ﬁnding novel drugs [2].
Even though current marine pharmacology is mainly
centered on the development of analgesic, anticancer, anti-
microbial, and cytotoxic agents [3, 4], the eﬀect of marine
natural products on other important diseases should be tar-
geted and explored.
The search for selective endothelin ETA receptor antago-
nists is still a top priority in the discovery of drugs to treat
cardiovascular disorders. Endothelin-1 (ET-1), a 21-amino-
acid residue peptide, is the most potent vasoconstrictor
known [5]. Its eﬀects are mediated via two G-protein-cou-
pledreceptors(GPCR),namely,ETA andETB,whicharecou-
pled to several subfamilies of the heterotrimeric G protein2 The Scientiﬁc World Journal
family, mainly Gq,G 11,G s,a n dG i2 [6]. During the develop-
ment of cardiovascular disease, the expression and biological
activities of ET-1 and its receptors are altered. Even though
mainly ETA receptors are located on vascular smooth muscle
cells, a few of the ETB receptors may also be present. Thus,
the vasoconstrictor eﬀect caused by ET-1 at this level is med-
iated by activation of both receptors [7]. The opposite eﬀect
is mediated by stimulation of the ETB receptor on the endo-
thelial cells by means of NO and prostacyclin [8]. Due to
this situation, the net eﬀect of ET-1 depends not only on the
balancebetweenETA andETB butalsoonthereceptorslocal-
ization. The available literature suggests that dual ETA/ETB
receptor antagonism is more eﬀective than selective ETA
receptor antagonism in order to fully prevent the deleterious
actions of ET-1 in cardiovascular disease [7]. However, the
question remains whether the blockade of ETB is desired,
since blocking this receptor delays the clearance of ET-1 in
the lungs thus keeping high levels of circulating ET-1 [9].
Adverse eﬀects are relatively common for the majority of
the known endothelin receptor antagonists in clinical trials
and seem to be related to nonspeciﬁc vasodilating eﬀects.
Themostcommonclinicaladverseeventsreportedhavebeen
headache, dizziness, nausea, peripheral edema, nasal con-
gestion, upper respiratory tract infection, sinusitis, dyspnea,
and chest pain [10]. For a better understanding on how a
drug can cause a pharmacological, a secondary, or an adverse
eﬀect, it is important to know the dynamics of the receptor
system. Antagonist ligands represent a large proportion of
therapeutic agents targeting GPCRs; their interactions with
the receptors have been widely characterized in terms of re-
ceptor binding and signal transduction [11]. However, the
corresponding lateral mobility of the diﬀerent receptor states
involved in the process remains poorly documented [12]
promoting the need to carry out more studies to unravel the
diﬀusion characteristics of GPCRs.
Homogeneous receptor assays based on ﬂuorescence like
ﬂuorescence correlation spectroscopy (FCS) allow insights
into the physiological regulatory mechanisms for membrane
receptors at the single molecular level [13]. As it operates in
real time and without disturbing the ligand-receptor inter-
action, FCS is a state-of-the-art tool for drug discovery of
natural products and for additional evaluation of their inter-
actions with pharmacological relevant targets on living cells.
This method applies statistical analysis for the description
of the studied system and for the analysis of the amplitudes
of spontaneous ﬂuctuations in the number of particles
occurring in a very small volume (fL) of a system to derive
conventional diﬀusion transport and chemical rate coeﬃ-
cients [14]. In measuring ligand-target interactions, auto-
correlation of the time-dependent ﬂuorescence signal allows
faster diﬀusing and slower diﬀusing ligands to be diﬀerenti-
ated as to their free and bound state. Figure 1 shows a typical
experimental setup for FCS. FCS has proven to be useful not
only in phytopharmaceutical research [15] but also to screen
large libraries of molecules with high reproducibility and
sensitivity [16].
The present work analyses the binding behaviour of
Alexa532-ET1, a newly synthesized ﬂuorescently labelled
ET-1 derivative, to the ETA receptor using FCS on living
Pinhole
Tube lens
Emitted light
Emission ﬁlter
Dichroite
Exciting laser beam
Sample
Objective
Collimator
Laser
Hardware correlator Detector
Figure 1: Experimental setup for ﬂuorescence correlation spec-
troscopy.
vascularsmoothmusclecells.TheFCStechniqueallowedthe
characterization of the two-dimensional diﬀusion behavior
of diﬀerent Alexa532-ET1/ETA receptor complexes and of
the inﬂuence of the ETA selective antagonist BQ123 as well
as that of the organic extract of the fungus Fusicladium sp.
on these receptor-ligand complexes.
2.MaterialsandMethods
2.1. Cell Lines, Chemicals, and Biochemicals. Rat vascular
smooth muscle A10 cells were purchased from DSMZ
(Braunschweig, Germany); Alexa Fluor 532 carboxylic acid
andsuccinimidylesterwerepurchasedfromInvitrogen-Mol-
ecular Probes (Leiden, The Netherlands). BQ-123 and ET-1
were obtained from Sigma (Taufkirchen, Germany).
2.2. Biological Material. Fungus Fusicladium sp. was isolated
from the marine sponge Amphimedon viridis collected by
SCUBA in Bastimentos Island National Park, Panama, Re-
public of Panama following the procedure described else-
where [17]. Colonies on P30 agar (1.25g/L peptone, 1.25g/L
yeastextract,3g/LD-glucose,20g/Lagar,30g/Lmarinesalt)
orangebrownatﬁrst,becomingdarkbrowninolderregions,
superﬁcial and immersed, compact with irregular margin,
not producing pigments into the agar. Hyphae hyaline, ﬁl-
amentous, septate, branched, containing lipid droplets, not
sporulating (See Supplementary Figure 1 in Supplementary
material available online at doi:10.1100/2012/524169). After
sequencing the ITS1-5.8S-ITS2 gene, the consensus sequence
of Fusicladium sp. was deposited in GenBank under the
accession number JN837045. The ethyl acetate extract of
Fusicladium sp. was prepared as previously described [17].
2.3. Synthesis of Alexa532-ET1. The Alexa532-labeled ET-1
derivative (Alexa532-ET1) was obtained from the reaction of
0.55mg ET-1 with an excess of activated ﬂuorophore Alexa
Fluor 532 carboxylic acid, succinimidyl ester in 225μL PBS
supplemented with 25μL of 1M sodium bicarbonate solu-
tion to adjust the pH to 8. The ratio of protein/dye was 1:2.
The mixture was protected from light and stirred at room
temperature for one hour. The ﬂuorescently monolabeledThe Scientiﬁc World Journal 3
ligand was puriﬁed by size exclusion chromatography on a
Superdex Peptide PC 3.2/30 column, bed dimensions 3.2–
300mm (GE Healthcare Life Sciences, Freiburg, Germany)
using PBS as the eluent, at a ﬂow rate of 100μL/min, and
withdetectionwavelengthsof240and525nm.Identiﬁcation
of monolabeled Alexa532-ET1 was conﬁrmed by MALDI-
TOF mass spectrometry on a Voyager STR DE instrument
(AB SCIEX, Darmstadt, Germany).
2.4. FCS Experiments. FCS measurements were performed
via confocal illumination of a volume element of 0.19 fL
in a ConfoCor 1 instrument (Zeiss, Jena, Germany) with a
C-Apochromat 63x, NA 1.2 objective for water immersion.
A dichroic ﬁlter and a band-pass ﬁlter (FT 540, EF 530–600)
(Andover,Salem,MA)separatedtheexcitationlightfromthe
emitted ﬂuorescence. Sample excitation was performed with
the514nmlineofanargonlaser.Thepowerofthelaserbeam
entering the sample was 2.4kW/cm2. The intensity ﬂuctu-
ations were detected by an avalanche photodiode (SPCM-
AQ Series, PerkinElmer Optoelectronics, Fremont, ON) and
were correlated with a digital hardware correlator (ALV-
5000, ALV, Langen, Germany). To calibrate the volume ele-
ment of observation for the experiments, a deﬁned con-
centration of tetramethylrhodamine (TMR) was used. From
the determined diﬀusion time constant of TMR and the
diﬀusion coeﬃcient D of 280μm2/s, the radio ω0 (0.20μm)
and z0 (1.08μm) of the volume element were determined.
Volume element positioning to the upper membrane of the
cell was performed by motor-aided scanning through the cell
in the z-direction (optoelectronical DC-servodrives, resolu-
tion of 0.1μm). For the FCS experiments, the focus was
placed at half maximal of ﬂuorescence intensity at the upper
membrane, taking in fast diﬀusing free ligand and slow dif-
fusing receptor-ligand complexes in the plasma membrane.
2.5. Cell Culture and Binding Studies. A10 cells were seeded
at a density of 5.0 × 104 on 18mm poly-D-lysine-coated
coverslips.ThecoverslipswereplacedinaNunc12wellplate,
a n dt h ec e l l sw e r ec u l t u r e df o r7d a y si nD u l b e c c o ’ sM o d i ﬁ e d
Essential Media supplemented with L-glutamine (2mM),
1% of a solution containing 10000I.U./mL penicillin and
10000μg/mL streptomycin (GIBCO, Invitrogen, Karlsruhe,
Germany) and 20% foetal calf serum. The cells were grown
in 5% CO2 at 37◦C until conﬂuence was reached.
Prior to the FCS measurements, cells were washed three
times with Locke’s solution (5mM HEPES, 154mM NaCl,
5.6mM KCl, 1mM MgCl2,3 . 6 m MN a 2CO3,2 . 0 m Mg l u -
cose, 2.3mM CaCl2 (pH 7.4)) at 37◦C. For the binding
studies,thecoverslipsweremountedonacarrierandthecells
were incubated for 45min with 300μLo fL o c k e ’ ss o l u t i o n
containing diﬀerent concentrations of Alexa532-ET1 (5–
55nM).
To determine the nonspeciﬁc binding, 1μM BQ123 was
added to cells which had been preincubated with diﬀerent
concentrations of Alexa532-ET1 for 45min. The incubation
with BQ123 lasted 30min. Similarly, 1μg/mL of fungal ex-
tract was added to cells preexposed to Alexa532-ET1 for
4 5m i na n da l l o w e dt oa c tf o r3 0m i n u t e sm o r ea t2 0 ◦C.
2.6. Inositol Phosphate Determination. The inositol phos-
phate determination assay was performed using the IP-One
ELISA Kit foradherent cells (CISBIO,Cedex, France)follow-
ing the operation instructions. To determine the agonistic
capacity of the newly synthesized Alexa532-ET1 ligand, A10
cellswereseededatadensityof10,000cellsperwellintoa96-
well plate (Nunc, Langenselbold, Germany) four days prior
to the experiment. The test substances were diluted in the
stimulation buﬀer to a ﬁnal concentration ranging from 0.5
to 50nM. Cells were incubated for 30 minutes before their
lysis. The supernatant was transferred into the ELISA plate
where the competitive immunoassay took place. After the
reactionwasstopped,theopticaldensitycorrespondingtoIP
accumulation was read at 450nm with Bio-Rad Microplate
Reader (Bio-Rad, Munich, Germany).
2.7. Data Evaluation. The autocorrelation function G(τ)f o r
j diﬀerent diﬀusing components in a three-dimensional
Gaussian volume element is given by the following equation:
G(τ) = 1+
n
j=1Q2
jNj
n
j=1QjNj
2
1
1+τ/τDj
    1
1+(ω0/z0)
2τ/τDj
(1)
with
τDj =
ω2
0
4Dj
, (2)
Qj = σjηjgj, (3)
where Nj is the average number of molecules of the species j
in the volume element, τDj is the diﬀusion time constant of
the species j, τ is the correlation time; ω0 is the radius of the
observation volume in the focal plane, z0 is the radius of the
observation volume in the z-direction, Dj is the translational
diﬀusion coeﬃcient of the species j;Qj is the quantum yield
factor, σj is the absorption coeﬃcient, ηj is the ﬂuorescence
quantum yield, and gj is the ﬂuorescence detection eﬃciency
of the species j.
2.8. Statistical Data Evaluation. All data points from FCS
measurements represent mean values and standard devia-
tions of six independent experiments. The statistical sig-
niﬁcance of results was proven with one factorial analysis
of variance (ANOVA). The results were considered to be
signiﬁcant for P values ≤0.05.
3. Results
The ligand Alexa532-ET1 was obtained by labelling ET-1
with Alexa Fluor 532 carboxylic acid, succinimidyl ester. The
structure of Alexa532-ET1 was conﬁrmed by MALDI-TOF
mass spectrometry (m/z 3099, [M-H]+).
For the experiment, the illuminated volume element was
positioned on the upper plasma membrane of the A10 cell.
Forty-ﬁve minutes after addition of 14.3nM Alexa532-ET1 a
total binding of 43.5 ± 12.3% (6.22 ± 1.7nM)wasfoundat4 The Scientiﬁc World Journal
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Figure 2: Comparison of autocorrelation curves of the Alexa532-
ET1(14.3nM)bindingtotheETA receptoronlivingA10cells.Con-
trol experiments (blue), coincubation with 1μM BQ-123 (green)
leads to an autocorrelation curve similar to that of the free ligand
(red) indicating the displacement of the bound Alexa532-ET1.
20◦C, and two diﬀusion time constants of τbound1 = 63.6 ±
41.6msandτbound2 = 1.8 ± 0.2ms(n = 6)ms were meas-
uredforthelateralmobilityofdiﬀerentstatesofthereceptor-
ligand complex in the plasma membrane (Figure 2). The dif-
fusion time constant τfree of 95.6 ± 9.0μs( n = 6) for the free
diﬀusing Alexa532-ET1 in solution was measured in inde-
pendent experiments and was kept constant in all ﬁtting pro-
cedures. Diﬀusion coeﬃcients were calculated from the dif-
fusion time constants using (2): Dfree = 104.2±9.0μm2/s for
free diﬀusing Alexa532-ET1, Dbound1 = 0.16 ± 0.06μm2/s
forreceptor-ligand complexes with hindered lateralmobility,
and Dbound2 = 5.6 ±0.6μm2/s for receptor-ligand complexes
with unrestricted mobility. Saturation of Alexa532-ET1
binding was observed at a total concentration of approxi-
mately35nM.ThedissociationconstantKd=6.77±2.54nM
and the maximum number of binding sites Bmax = 7.70 ±
0.74nM were obtained from a plot of the bound ligand
versus the total amount of the ligand by nonlinear curve
ﬁtting (Figure 3). The maximum concentration of bound
ligand(Bmax)isthesameasthemaximumnumberofbinding
sites in the sample and corresponds to receptor density in the
cell membrane. For an average observed membrane area of
0.13μm2 (πω2
0),areceptordensity(r)o f59.2±5.7r ec e pt o r s /
μm2 (n = 6) (Bmax)/(πω2
0) was found.
In equilibrium, 6.22 ± 1.7nM of 14.3nM Alexa532-ET1
was bound to the ETA receptor (Table 1). While 2.3±0.7nM
o ft h eb o u n dl i g a n d( =16.0 ± 5.2% of total Alexa532-ET1)
showed hindered diﬀusion behavior, represented by Dbound1;
3.9 ± 1.0nM of receptor-ligand complexes (=27.5 ± 7.0%
of total Alexa532-ET1) showed unrestricted lateral mobility,
represented by Dbound2.NonlabeledET-1aswellasAlexa532-
ET1 showed a dose-dependent increase of inositol phosphate
(IP1) production up to 70–80nM in A10 cells (Figure 4).
In the same line, the binding of 14.3nM Alexa532-ET1 was
inhibited by 1μM of the selective ETA antagonist BQ-123
(only 82%± or 1.1 ± 0.3nM of the remaining binding was
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Figure 3: Alexa532-ET1 binding to vascular smooth muscle cells.
Averaged bound Alexa532-ET1 concentration versus the total
Alexa532-ET1 concentration. The bound Alexa532-ET1 fraction
was determined from the autocorrelation function for diﬀerent
Alexa532-ET1 concentrations (n = 5).
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Figure 4: Results of the inositol phosphate (IP1) production assay
after stimulation of A10 cells with diﬀerent concentrations of
nonlabeled endothelin 1 and Alexa532-ET1. Data are presented as
the mean ± SEM of eight measurements.
nonspeciﬁc) conﬁrming the speciﬁc binding of Alexa532-
ET1 to the ETA receptor on A10 cells (Table 1).
After 10min preincubation with 1μM BQ-123, the time-
dependent binding of 5nM Alexa532-ET1 was investigated,
andafter15minatotalbindingof14.4 ± 5.1%wasfound.At
30min a total binding of 32.9 ± 3.9% (1.6 ± 0.2n Mo fn o n -
speciﬁc binding) was observed and was stable up to 60min.
Remarkably, the binding of the ligand was found only for the
unrestricted diﬀusing receptor-ligand complex with τbound2.
Furthermore, the extract of Fusicladium sp. (1μg/mL)
inhibited the binding of Alexa532-ET1 (7.4nM). Whereas
the receptor-ligand complex with Dbound1 was completely
displaced, 22 ± 6% (1.6 ± 0.4nM) of the receptor-ligand
complex with Dbound2 was found (Table 1).The Scientiﬁc World Journal 5
Table 1: FCS binding studies with Alexa532-ET1 on endothelin ETA receptor.
Binding of Alexa532-ET1 to A10 cells Free L with Dfree [%] R-L with Dbound1 [%] R-L with Dbound2 [%]
Control(a) 56.5 ±8.51 6 .0 ±5.22 7 .5 ±7.0
Displacement with 1μM BQ-123 after 30min(a) 92 ±25 ±23 ±1
Displacement with 1μg/mL fungal extract after 30min(b) 78 ±6N . D .2 2 ±6
L indicates Alexa532-ET1 14.3nM(a), 7.4nM(b); R-L: the receptor-ligand complex; N.D.: not detectable.
4. Discussion
FCS provided a more complete description of the pharma-
cological proﬁle of the drug-system complexes considered.
With this technique, it was possible to study the lateral mo-
bility of the receptor-ligand complexes in the plasma mem-
braneandrecognizehowthedownstreamresponsesinvolved
in receptor-ligand interactions are capable of inﬂuencing
these dynamics. The plasma membrane is characterized by
complex dynamic heterogeneous distributions of lipids and
proteins, which are believed to have functional implications
[18]. Only a complete description of the dynamic organi-
zation of the signaling partners by investigating their mem-
brane diﬀusion behavior will lead to a full understanding of
GPCR signal transduction mechanisms [8]. These mecha-
nisms control physiological and side eﬀects of any drug, as
illustrated by studies on μ opioid receptors [19].
For a better understanding of the endothelin system, a
homogeneous ETA receptor assay on living A10 cells using
the ﬂuorescently labeled ligand Alexa532-ET1 was estab-
lished and validated. The FCS model on A10 cells showed
ar e c e p t o rd e n s i t yo f5 9 .2 ±5.7r e c e p t o r s / μm2 w h i c hi sc o m -
parable with 45 ± 11ETA receptors/μm2 from aortas of New
Zealand white rabbits [20]. Furthermore, the Alexa532 moi-
ety did not inﬂuence the binding behavior of ET-1, since a
high binding aﬃnity for Alexa532-ET1 with a KD = 6.77 ±
2.54nMwasalsofound,whichcorrespondstoﬁndingsmade
on cloned bovine ETA receptors (KD = 20 pM to 1nM) [21].
Throughout the literature, KD values as low as a few pico-
molars and as high as a few nanomolars have been reported
for endothelin receptor subtypes [21–23]. It is important to
point out that ET-1 binding is never analyzed under true
equilibrium conditions, since the ET-1/receptor complexes
dissociate slowly and incubation times of more than 20h are
necessary to reach thermodynamic equilibrium, which may
lead to artiﬁcially high apparent KD values [21].
A displacement experiment using 1μM of the selective
ETA receptor antagonist BQ123 showed a nonspeciﬁc bind-
ing of 8 ± 2% which clearly demonstrated the speciﬁc inter-
action of Alexa532-ET1 with the ETA receptor. After 45min
incubation with 14.3nM of Alexa532-ET1, a detailed eval-
uation of the bound Alexa532-ET1 showed two diﬀusion
time constants of τbound1 = 63.6 ± 41.6ms and τbound2 =
1.8 ± 0.2ms(n = 6) associated with two diﬀerent receptor-
ligandstates.Asimilarsituationwithaslowandfastdiﬀusing
receptor-ligand complex was found for diﬀerent GPCR sys-
tems [13], for instance, the β2-adrenergic receptor in C6
Glioblastoma cells, hippocampal neurons, alveolar epithelial
type II cells (A549) [13, 15], and the GABAA receptor in
hippocampal neurons [24, 25]. From the diﬀusion time
constants, three diﬀerent diﬀusion coeﬃcients (Dbound1,
Dbound2,a n dDfree) were calculated for the diﬀerent states
of mobility of the receptor-ligand complex and the ligand.
The diﬀusion coeﬃcient found for Alexa532-ET1 (Dfree =
104.2 ± 9.0μm2/s) is comparable to that found for the
tetramethylrhodamine derivative (Dfree = 140.5±2.5μm2/s)
[22], showing no eﬀect of the selected ﬂuorescent dye on the
ET-1 binding characteristics. During the signal transduction,
the ETA receptor interacts with several regulatory molecules
like phosphatidylinositol-speciﬁc phospholipase C, inositol-
triphosphate, diacylglycerol [26], cytoskeleton proteins and
G-protein-coupled receptor kinases (GRKs). For instance, it
has been shown that, in HEK 293 cells transfected with the
human ETA and ETB receptors, ET-1-induced desensitiza-
tion corresponded temporally with agonist-induced receptor
phosphorylation, and appeared to involve the action primar-
ily of GRK2 rather than other GRKs or protein kinase C [27].
In addition to receptor desensitization, internalization of the
receptor-bound ligand is a common method of signal termi-
nation, which, for the case of the ETA receptor, is mediated
via caveolae, with subsequent degradation of at least a por-
tion of the bound ligand [28]. These interactions are capable
of changing the diﬀusion behavior of the receptor. To our
knowledge, this is the ﬁrst time the ETA receptor-ligand in-
teractions have been studied on living cells in real time.
FCS allowed the discrimination of two diﬀerent states for
the ETA receptor. However, other techniques such as single
particle tracking enable the detection of additional receptor
states, since it is possible to track the lateral mobility of a
singlereceptor-ligandcomplexonlivingcells[12]andobtain
a more complete pharmacological proﬁle of the receptor.
As described above, a hindered diﬀusing receptor is asso-
ciated with complex molecular interactions, which can be
interpreted as receptors going into internalization processes
or “inactive” states, whereas unrestricted diﬀusing receptors
can be identiﬁed as receptors in “active” states. For the ETA
receptor model described here, as well as for the GABAA and
the β2-adrenergic receptor models described elsewhere [15,
24, 25], the proportion of the fast diﬀusing receptor-ligand
complexes was higher than that of slow diﬀusing receptor-
ligand complexes [15, 24, 25]. These ﬁndings support the
multistate receptor model, where the population of “active”
receptor states increase after agonist binding [29]. After pre-
incubation of the cells with 1μM BQ123 for 10min, we
investigated the binding behavior of 5nM Alexa532-ET1
time dependently. After 15min we found a total binding of
14.4 ± 5.1% which increased up to 32.9 ± 3.9% after 30min
and was then stable after 60min. Surprisingly, the binding6 The Scientiﬁc World Journal
of the ligand was selectively found for unrestricted diﬀusing
receptor-ligand complexes, suggesting that BQ-123 showed a
strongbindingaﬃnitytothe“inactive”receptorstatecharac-
terized by the slow diﬀusion time constant τbound2. A similar
eﬀect was observed for the ethyl acetate extract of the fungus
Fusicladium sp., which completely displaced Alexa532-ET1
fromitsbindingtothe“inactive”receptorstate.Interestingly,
a substance with a higher aﬃnity for the “inactive” receptor
state is known as inverse agonist [30] .I n v e r s ea g o n i s mi sw e ll
known for benzodiazepine receptors as well as many other
GPCRs [31]. A previous study showed that GABAA receptor
binding studies using FCS on hippocampal neurons revealed
an increased binding of Alexa532-muscimol mediated by the
positive cooperative activity of coincubated benzodiazepines
(e.g., midazolam), which was selectively found in GABAA
receptor-ligand complexes with hindered lateral mobility
[24].Theseﬁndings suggestthatbothBQ-123andthefungal
extract act as inverse agonists of ETA receptors on A10 cells,
a property that can easily be detected by FCS.
The major advantage FCS being over other ligand-
receptor binding assays such as radio-receptor assays is that
the interaction receptor-ligand is not inﬂuenced at any level
during the evaluation. The data are evaluated in living vas-
cularsmoothmusclecellswithoutdisturbanceofthebinding
dynamics, allowing us to show the behavior of the ETA re-
ceptor in its natural environment. FCS oﬀers a state-of-the-
art tool for drug discovery of natural products and the eval-
uation of their interactions with pharmacological relevant
targets.
WhereasFCSprovidesaveragemeasurements,singlepar-
ticle tracking (SPT) acquires the trajectories of single molec-
ules [12]. SPT studies are more informative regarding the
molecular events following the binding of GPCR to antago-
nist and agonist ligands. Forthcoming research will study the
diﬀusion characteristics of the ETA receptor using SPT and
Alexa532-ET1.
G-protein-coupled receptors, such as ETA, possess com-
plex multimolecular machinery regulating signal transduc-
tion pathways responsible for their biological eﬀects. We
believe that understanding the functional dynamics of the
ETA receptor will enable us to propose speciﬁc targets for the
development of more selective antihypertensive drugs.
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